Form 8-K - Current report:
SEC Accession No. 0001140361-24-039592
Filing Date
2024-08-30
Accepted
2024-08-30 08:30:16
Documents
13
Period of Report
2024-08-27
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K ef20035237_8k.htm   iXBRL 8-K 24798
  Complete submission text file 0001140361-24-039592.txt   162508

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA eltx-20240827.xsd EX-101.SCH 3859
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE eltx-20240827_lab.xml EX-101.LAB 22690
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE eltx-20240827_pre.xml EX-101.PRE 16548
15 EXTRACTED XBRL INSTANCE DOCUMENT ef20035237_8k_htm.xml XML 4225
Mailing Address 451 D STREET, 5TH FLOOR BOSTON MA 02210
Business Address 451 D STREET, 5TH FLOOR BOSTON MA 02210 (857) 209-0050
Elicio Therapeutics, Inc. (Filer) CIK: 0001601485 (see all company filings)

EIN.: 113430072 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39990 | Film No.: 241266056
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)